The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload.
Digital Pathology, seen as a great potential for productivity enhancement, has not fully delivered on that promise. Some ROI studies have, at best, demonstrated marginally positive return on investment with others demonstrating negative impact on cost post implementation.
We believe that digital pathology combined with artificial intelligence will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.
Deciphex plan to be at the forefront of this revolution with cleverly positioned solutions, that deliver on the biggest problems facing pathology today.
Ergonomic workflows integrated with artificial intelligence to optimise pathologist productivity is key in delivery of Deciphex solutions.
Deciphex places the emphasis on triaging out of high volume, low complexity samples, allowing pathologists the time needed to focus on difficult, more challenging content.
Deciphex are focussed on integrating the highest quality proprietary annotated data sets for deep learning development and validation.
Deciphex targets Human Gastrointestinal and Toxicologic Pathology use cases rather than attempting a one size fits all approach.
Donal is an experienced corporate officer in the technology and diagnostics sectors, having 20 years of business leadership experience from start-up through to large corporate enterprise. He is an innovator with a proven track record in developing diagnostics products from concept to market. Donal has founded three companies, and has senior management experience in Slidepath, Genetix, Leica Microsystems and Leica Biosystems. Donal has had considerable M&A experience with experience of both successful trade sales and acquisitions. Donal holds a Degree and Ph.D. in Biotechnology from Dublin City University (DCU), HRB postdoctoral fellowship and was also a member of the academic staff in the School of Biotechnology in DCU. Donal is a non-executive director on a number of lifescience and diagnostics businesses.
Mark is an expert in image analysis, machine learning and pattern recognition. He has over 30 years’ experience developing slide scanning and image analysis products for cytogenetics and pathology. Systems developed under his leadership have converted to over $250m in sales worldwide. Mark has considerable experience in diagnostic product regulation and intellectual property protection, authoring several technology patents. He has held several senior R&D roles (Director of R&D Image Analysis and Clinical Solutions for Leica Biosystems, R&D Manager Clinical Imaging for Leica Microsystems, VP Imaging Development for Genetix). Mark is focused on developing integrated solutions that provide tangible improvement to workflow efficiency. Mark holds a degree from Newcastle University and a diploma from Teesside University.
Mairin is an experienced COO with >15 years experience in startups and academia. She has considerable experience in operational management, research funding, research programme management and generating IP portfolios. As COO of diagnostics start-up Oncomark, she was responsible for obtaining and managing ~€7M in EU research funding, including €2.75M under the EU SME Instrument program. In Oncomark, she managed all company activities, including defining business strategy, financial, HR and IP. She has also been involved managing significant venture capital investment processes and EU financial audits. Mairin holds a degree and PhD from University College Dublin and an MBA from Trinity College Dublin. Following her PhD she held postdoctoral scientist positions in the Fox Chase Cancer Centre, Philadelphia, and in the Conway Institute, UCD.
Andrea is an experienced software consultant having 10+ years of proven track record covering wide range of technical roles, using different technologies and paradigms. Andrea has delivered cutting-edge cloud solutions in a range fields such as GIS, Healthcare and Finance. He has worked as technical lead on key projects in FAA and Mastercard where project success has driven true competitive differentiation. Andrea has worked as senior software architect in Slidepath and Leica Biosystems developing significant knowledge of the pathology sector. Andrea has a degree in Computer Science (UCD) and a Master of research of Computer Science (UCD, DIT) in MEMS (Mobile Environmental Management Systems). He has made contribution of the field of GIS with two published papers in the W2GIS.
Shane is an experienced, results-oriented manager with 12+ years’ experience in multinational companies. Most recently Shane spent 8+ years in Leica Biosystems working in an ISO13485 regulated environment and leading the Technical Support team for pathology imaging products. Customer experience and developing trust with key stakeholders at varying levels of customer organisations has been and continues to be a critical part of his role. Along with and through his team, Shane delivered complex problem solving, identification of trends and implementation of effective countermeasures while keeping focus on Customer Experience. Shane believes there is no problem that cannot be solved through Constant Improvement. Shane holds an honours degree in Information and Communications Technology from Trinity College Dublin.
Colin has worked in the Digital Pathology sector for 15 years, bringing with him a wealth of experience in the design and delivery of innovative software products for the Healthcare, Life Science & Academic segments. A graduate in Biotechnology from Dublin City University, Colin has worked in both dynamic Start-Up and Large Corporate organisations, fulfilling a broad remit of customer-facing roles in Business Development, Sales, Commercial Marketing and Product Management. He has previously led the Software Product Management team at Leica Biosystems (a Danaher Company), defining and driving execution of commercial strategies for both Medical Device (IVD) and Research Use products across different geographies.
Deciphex and Charles River Laboratories International, Inc. (NYSE: CRL) have jointly announced today that they are the first in the industry to offer clients Good Laboratory Practice (GLP) validated digital peer review, using Deciphex Patholytix Preclinical for toxicologic pathology.
At Deciphex our mission is to enable our users to facilitate digital peer review of non-clinical pathology studies. We are delighted to announce the upcoming launch of Patholytix Preclinical 2.0 which provides our clients with a pathway to a regulated GLP Peer Review in conjunction with their CRO partners.
By combining Deciphex’s unique digital pathology solutions with Cernostics tissue systems pathology approach, the partnership aims to generate novel predictive indicators using AI.
Invent, DCU, Dublin 9, Ireland